* Inovio Pharmaceuticals Inc reported a quarterly adjusted loss of 89 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.56. The mean expectation of six analysts for the quarter was for a loss of $1.15 per share. Wall Street expected results to range from $-1.24 to -94 cents per share.
* Reported revenue was zero; analysts expected $104.50 thousand.
* Inovio Pharmaceuticals Inc's reported EPS for the quarter was a loss of 89 cents.
* The company reported a quarterly loss of $25.17 million.
* Inovio Pharmaceuticals Inc shares had fallen by 17.5% this quarter and lost 22.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is 13.50 This summary was machine generated from LSEG data November 15 at 02:03 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.15 -0.89 Beat
Jun. 30 2024 -1.10 -1.19 Missed
Mar. 31 2024 -1.00 -1.31 Missed
Dec. 31 2023 -1.27 -1.12 Beat
Comments